Clinical trials: FAPI
Rectal Cancer, Lymph Node Metastases
Comparison of [68Ga]Ga-CTR-FAPI and 18F-FDG PET/MRI for Lymph Node Staging in Rectal Cancer
This is a prospective, single-center, diagnostic study designed to compare the accuracy of [68Ga]Ga-CTR-FAPI PET/MRI and [18]F-FDG PET/MRI for the detection of lymph node metastasis in patients with initially untreated…
- Conditions
- Rectal Cancer, Lymph Node Metastases, PET / MR
- Trial name
- PKUCH-R12 (NCT07552207)
- Testing
- PET/MRI with 18F-FDG and [68Ga]Ga-CTR-FAPI
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Neoplasms
Evaluation Using FAPI-PET Targeting Cancer-associated Fibroblasts
PET / CT examination using [18F] FAPI-74 is performed on patients diagnosed with malignant tumor, and the pathological condition is determined by comparing with FDG-PET/CT examination of conventional diagnostic imaging.
- Trial name
- NCT05442151
- Testing
- PET/CT ([F-18]FAPI-74)
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Tadashi Watabe
Thyroid Eye Disease
Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.
This is a prospective study designed to evaluate the efficacy and safety of Teprotumumab N01 in patients with Thyroid Eye Disease (TED).
- Trial name
- NCT07423013
- Testing
- [18F]AlF-NOTA-FAPI-04PET/CT, 5.0-T high-resolution MRI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Solid Tumor
Clinical Applications of FAPI PET in Solid Tumors
The study systematically evaluates the diagnostic performance of FAPI-RuiJ and FAPI-04 PET/CT or PET/MR in various solid tumor types, and is expected to provide a novel molecular imaging tool for early lesion detection, accurate…
- Trial name
- NCT07776899
- Testing
- FAPI-RuiJ, FAPI-04
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Ruijin Hospital
Breast Cancer, Metastatic Invasive Lobular Breast Cancer
Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
This study is a pilot clinical imaging trial of a prospective, head-to-head comparison of 18F-Fibroblast Activation Protein Inhibitor (FAPI)-74 PET/CT versus standard-of-care 18F-Fluorodeoxyglucose (FDG) PET/CT in 15 patients…
- Trial name
- NCT07285993
- Testing
- 18F-FAPI-74, 18F-FDG, PET/CT
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Randy Yeh
Fibrosis, Positron-Emission Tomography
68Ga-FAPI PET/CT in Patients With Various Fibrotic Disease
To evaluate the potential value of 68Ga-FAPI-04 positron emission tomography/ computed tomography (PET/CT) for the diagnosis and prognosis in fibrotic disease
- Trial name
- NCT04831034
- Testing
- 68Ga-FAPI-04
- Where
- China
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Liver Cancer
[18F]FAPI PET/CT in Suspicious Focal Liver Lesions Without FDG Avidity
Fibroblast activation protein (FAP) is a serine protease that belongs to the dipeptidyl peptidase-IV (DPP-IV) family located in fbroblast membranes.
- Trial name
- NCT05806333
- Testing
- FAPI PET
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jilin University
Cancer
68-Ga-FAPI PET Imaging in Malignancy
This feasibility trial studies the use of gallium-68 (68Ga)-FAPI as the imaging agent for positron emission tomography (PET)/computed tomography (CT), collectively PET/CT, in patients with various cancers.
- Trial name
- NCT04023240
- Testing
- 68Ga-FAPI, Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan
- Where
- United States
- Sponsor
- Stanford University
Tumor, Solid, Positron-Emission Tomography
Comparison of FDG and FAPI in Patients With Various Types of Cancer
To evaluate the potential usefulness of 68Ga-DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 18F-FDG PET/CT.
- Conditions
- Tumor, Solid, Positron-Emission Tomography, Metastasis
- Trial name
- NCT04416165
- Testing
- 18F-FDG and 68Ga-DOTA-FAPI -04 PET/CT
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Patients With Advanced Metastatic FAP-Positive Tumors
Clinical Study of 177Lu-JH040182 in Patients With FAP-Positive Malignancies
This first-in-human study aimed to assess the safety and internal radiation dosimetry of 177Lu-JH040182, a novel FAP-targeted radiopharmaceutical, in patients with FAP-positive tumors.
- Trial name
- NCT07681141
- Testing
- 177Lu-JH040182 with an activity of approximately 5.55-7.50 GBq
- Where
- China
- Volunteers
- 3 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Liver Metastases From Colorectal Cancer
The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases
FAPI PET/CT molecular imaging represents a cutting-edge advancement in oncological imaging, particularly for the preoperative assessment of colorectal liver metastases (CRLM).
- Trial name
- FOAM (NCT07109440)
- Testing
- FAPI PET/CT
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Jules Bordet Institute
PDAC
68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma
Fibroblast activation protein (FAP) is overexpressed in cancer-associated fibroblasts (CAFs), which constitutes a major proportion of cells within the tumor microenvironment, especially in primary pancreatic ductal carcinoma…
- Trial name
- NCT05275985
- Testing
- 68Ga-FAPI Positron Emission Tomography-Computed Tomography
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Malignant Neoplasm in the Prostate Gland, Prostate Carcinoma
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
This exploratory study investigates how a new imaging technique called FAPI PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with prostate cancer.
- Conditions
- Metastatic Malignant Neoplasm in the Prostate Gland, Prostate Carcinoma, Recurrent Prostate Carcinoma
- Trial name
- FAPI PET Prost (NCT04457232)
- Testing
- Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Oesophageal Cancer, Gastric Cancer
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
The aim of the project is to demonstrate superior detection ratio of [18F]AlF-FAPI-74 PET/CT compared to [18F]FDG PET/CT or conventional imaging in treatment-naïve, newly diagnosed patients with oesophagogastric adenocarcinoma…
- Conditions
- Oesophageal Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma, FAP
- Trial name
- FAPIDO (NCT06782412)
- Testing
- [18F]AlF-FAPI-74 PET/CT
- Where
- 3 sites in Belgium
- Volunteers
- 109 people
- Sponsor
- KU Leuven
Carcinoma, Intraductal, Noninfiltrating
Multimodal Imaging With FAPI-PET/MRI in Breast Carcinoma-In-Situ for Detection of Occult Invasive Cancer
DCIS (ductal carcinoma in situ) is a common pre-stage for breast cancer. The goal of this clinical trial is to learn if FAPI-PET/MRI (an imaging technique with a weakly radioactive drug) helps to diagnose hidden invasive breast…
- Trial name
- MI-CISDIR (NCT06540872)
- Testing
- [68Ga]Ga-FAPI-46
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Universität Münster
Ovarian Cancer
[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer
Fifty (n=50) patients with newly diagnosed ovarian cancer will undergo FAPI PET/CTs in addition to routine diagnostic workup (including FDG PET/CT) at primary staging and restaging.
- Trial name
- NCT05903807
- Testing
- 68Ga-FAPi-46
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Aalborg University Hospital
Nonischemic Cardiomyopathy
FAPI PET Imaging in Nonischemic Cardiomyopathy
This study aims to evaluate the clinical value of [¹⁸F]AlF-NOTA-FAPI-04 PET/CT for the noninvasive assessment of myocardial fibroblast activation in patients with nonischemic cardiomyopathy.
- Trial name
- FAPI-NICM (NCT07878338)
- Testing
- [¹⁸F]AlF-NOTA-FAPI-04
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer, Metastatic Breast Cancer
Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer
The purpose of this study was to explore the predictive value of the heterogeneity of 68Ga-FAPI PET-CT uptake before treatment on the response of T-DXd treatment in patients with brain metastases of HER2-positive breast cancer.
- Trial name
- NCT06797622
- Testing
- Trastuzumab deruxtecan (T-DXd)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Tumor, Positron-Emission Tomography
68Ga-FAPI PET/CT in Patients With Various Types of Cancer
To evaluate the potential usefulness of 68Ga-DOTA/NOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer.
- Conditions
- Tumor, Positron-Emission Tomography, Metastasis
- Trial name
- NCT04499365
- Testing
- 68Ga-DOTA/NOTA-FAPI-04, PET/CT scan
- Where
- China
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Lung Adenocarcinoma, 18F-FDG
18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma
To evaluate the potential usefulness of 68Ga-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in lung adenocarcinoma, compared with 18F-FDG PET/CT.
- Conditions
- Lung Adenocarcinoma, 18F-FDG, 68Ga-FAPI, PET/CT
- Trial name
- NCT04588064
- Testing
- 68Ga-FAPI PET/CT scan
- Where
- China
- Volunteers
- 63 people
- Sponsor
- The First Affiliated Hospital of Xiamen University